舒血宁联合依帕司他治疗糖尿病肾病的临床疗效  

Clinical efficacy of Shuxuening injection combined with epalrestat for diabetic nephropathy

作　　者：刘景文[1] 田义梅[2] 钟燕[1] 杨荣静[2] 陈莉明[3] 

机构地区：[1]天津市第二医院药剂科,天津300141 [2]天津市北辰医院药剂科,天津300400 [3]天津医科大学代谢病医院代谢病科,天津300070

出　　处：《中国生化药物杂志》2015年第12期155-157,共3页Chinese Journal of Biochemical Pharmaceutics

基　　金：国家自然科学基金面上项目(81273915)

摘　　要：目的观察研究舒血宁联合依帕司他治疗糖尿病肾病的临床疗效。方法选取天津市第二医院代谢病科2014年3月~2015年6月收治的确诊为糖尿病肾病的患者共80例,按随机数字表法分为观察组和对照组各40例,对照组给予依帕司他治疗,观察组在对照组治疗基础上予舒血宁注射液治疗,随访并记录2组患者相关指标变化情况。结果观察组患者治疗后24 h尿微量白蛋白、血浆低密度脂蛋白、血肌酐[（239.31±106.54）mg/L、（2.45±0.55）mmol/L、（95.54±22.13）mol/L]水平显著低于对照组[（349.90±148.40）、（3.41±0.52）、（108.76±34.30）]（P〈0.05）。观察组治疗后尿β2微球蛋白（β2-microglobulin,β2-MG）和血浆超敏C反应蛋白（high-sensitive C-reactive protein,hs-CRP）[（0.39±0.06）、（6.31±1.58）mg/L]显著低于对照组[（0.49±0.12）、（7.89±1.35）]（P〈0.05）。观察组总显效率高于对照组（70.0%vs.45.0%,P〈0.05）。结论舒血宁联合依帕司他治疗糖尿病肾病的临床治疗效果确切。Objective To explore the clinical efficacy of Shuxuening combined with epalrestat in the treatment of diabetic nephropathy.Methods Eighty patients from March 2014 to June 2015 in Metabolic Disease Department of the Second Hospital of Tianjin were randomly divided into observation group and control group with 40 patients in each group. The control group received epalrestat,and the observation group received Shuxuening injection on the baisis of control group. The related indicators were compared between two groups. Results After treatment, the 24 h-urine microalbumin,plasma low density lipoprotein and serum creatinine in observation group [（ 239. 31 ± 106. 54） mg / L,（ 2. 45 ± 0. 55） mmol / L,（ 95. 54 ±22. 13） mol / L]were lower than those in control group [（ 349. 90 ± 148. 40）,（ 3. 41 ± 0. 52）,（ 108. 76 ± 34. 30） ]（ P〈0. 05）. The β2-microglobulin（ β2-MG） and plasma high-sensitive C-reactive protein（ hs-CRP） in observation group [（ 0. 39 ± 0. 06）,（ 6. 31 ± 1. 58） mg/L]were lower than those in control group [（ 0. 49 ± 0. 12）,（ 7. 89 ± 1. 35） ]（ P〈0. 05）. The total efficacy in observation group was higher than that in control group（ 70. 0%vs. 45. 0%,P〈0. 05）. Conclusion Shuxuening injection joint epalrestat has the exact efficacy in treatment of patients with diabetic nephropathy.

关 键 词：舒血宁注射液 依帕司他 糖尿病肾病 联合用药 

分 类 号：R692[医药卫生—泌尿科学]